Jakoba Johanna Eertink

Jakoba Johanna Eertink

Auto-generated profile, based on publicly available information

Jakoba Johanna Eertink

Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
N. George MikhaeelN. George Mikhaeel
N. George Mikhaeel
MHMartijn W. Heymans
Martijn W. Heymans
JEJakoba J. Eertink
Jakoba J. Eertink
HVHenrica C.W. de Vet
Henrica C.W. de Vet
RBRonald Boellaard
Ronald Boellaard
SBSally F. Barrington
Sally F. Barrington
PURPOSE: Baseline metabolic tumor volume (MTV) is a promising biomarker in diffuse large B-cell lymphoma (DLBCL). Our aims were to determine the best statistical relationship between MTV and survival and to compare MTV with the International Prognostic Index (IPI) and its individual components to derive the best prognostic model. METHODS: PET scans and clinical data were included from five published studies in newly diagnosed diffuse large B-cell lymphoma. Transformations of MTV were compared with the primary end points of 3-year progression-free survival (PFS) and overall survival (OS) to derive the best relationship for further analyses. MTV was compared with IPI categories and individual components to derive the best model. Patients were grouped into three groups for survival analysis using Kaplan-Meier analysis; 10% at highest risk, 30% intermediate risk, and 60% lowest risk, corresponding with expected clinical outcome. Validation of the best model was performed using four studies as a test set and the fifth study for validation and repeated five times. RESULTS: The best relationship for MTV and survival was a linear spline model with one knot located at the median MTV value of 307.9 cm3. MTV was a better predictor than IPI for PFS and OS. The best model combined MTV with age as continuous variables and individual stage as I-IV. The MTV-age-stage model performed better than IPI and was also better at defining a high-risk group (3-year PFS 46.3% v 58.0% and 3-year OS 51.5% v 66.4% for the new model and IPI, respectively). A regression formula was derived to estimate individual patient survival probabilities. CONCLUSION: A new prognostic index is proposed using MTV, age, and stage, which outperforms IPI and enables individualized estimates of patient outcome.

18 August 2021 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
JEJakoba J. Eertink
Jakoba J. Eertink
TBTim van de Brug
Tim van de Brug
SWSanne Elisabeth Wiegers
Sanne Elisabeth Wiegers
GZGerben JC Zwezerijnen
Gerben JC Zwezerijnen
EPElisabeth A. G. Pfaehler
Elisabeth A. G. Pfaehler
JZJosée M. Zijlstra
Josée M. Zijlstra
Purpose: Accurate prognostic markers are urgently needed to identify diffuse large B-Cell lymphoma (DLBCL) patients at high risk of progression or relapse. Our purpose was to investigate the potential added value of baseline radiomics features to the international prognostic index (IPI) in predicting outcome after first-line treatment. Methods: Three hundred seventeen newly diagnosed DLBCL patients were included. Lesions were delineated using a semi-automated segmentation method (standardized uptake value ≥ 4.0), and 490 radiomics features were extracted. We used logistic regression with backward feature selection to predict 2-year time to progression (TTP). The area under the curve (AUC) of the receiver operator characteristic curve was calculated to assess model performance. High-risk groups were defined based on prevalence of events; diagnostic performance was assessed using positive and negative predictive values. Results: The IPI model yielded an AUC of 0.68. The optimal radiomics model comprised the natural logarithms of metabolic tumor volume (MTV) and of SUVpeak and the maximal distance between the largest lesion and any other lesion (Dmaxbulk, AUC 0.76). Combining radiomics and clinical features showed that a combination of tumor- (MTV, SUVpeak and Dmaxbulk) and patient-related parameters (WHO performance status and age > 60 years) performed best (AUC 0.79). Adding radiomics features to clinical predictors increased PPV with 15%, with more accurate selection of high-risk patients compared to the IPI model (progression at 2-year TTP, 44% vs 28%, respectively). Conclusion: Prediction models using baseline radiomics combined with currently used clinical predictors identify patients at risk of relapse at baseline and significantly improved model performance. Trial registration number and date: EudraCT: 2006–005,174-42, 01–08-2008.

4 May 2021 in Blood Advances
Verified
Journal Article
Open access
PDF file
JEJ. J. Eertink
J. J. Eertink
CBC. N. Burggraaff
C. N. Burggraaff
MHM. W. Heymans
M. W. Heymans
UDU. Dührsen
U. Dührsen
AHA. Hüttmann
A. Hüttmann
HVH. C. W. de Vet
H. C. W. de Vet
Interim 18F-fluorodeoxyglucose positron emission tomography (Interim-18F-FDG-PET, hereafter I-PET) has the potential to guide treatment of patients with diffuse large B-cell lymphoma (DLBCL) if the prognostic value is known. The aim of this study was to determine the optimal timing and response criteria for evaluating prognosis with I-PET in DLBCL. Individual patient data from 1692 patients with de novo DLBCL were combined and scans were harmonized. I-PET was performed at various time points during treatment with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy. Scans were interpreted using the Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Multilevel Cox proportional hazards models corrected for International Prognostic Index (IPI) score were used to study the effects of timing and response criteria on 2-year progression-free survival (PFS). I-PET after 2 cycles (I-PET2) and I-PET4 significantly discriminated good responders from poor responders, with the highest hazard ratios (HRs) for I-PET4. Multivariable HRs for a PET-positive result at I-PET2 and I-PET4 were 1.71 and 2.95 using DS4-5, 4.91 and 6.20 using DS5, and 2.93 and 4.65 using ΔSUVmax, respectively. ΔSUVmax identified a larger proportion of poor responders than DS5 did. For all criteria, the negative predictive value was >80%, and positive predictive values ranged from 30% to 70% at I-PET2 and I-PET4. Unlike I-PET1, I-PET3 discriminated good responders from poor responders using DS4-5 and DS5 thresholds (HRs, 2.94 and 4.67, respectively). I-PET2 and I-PET4 predict good response equally during R-CHOP therapy in DLBCL. Optimal timing and response criteria depend on the clinical context. Good response at I-PET2 is suggested for de-escalation trials, and poor response using ΔSUVmax at I-PET4 is suggested for randomized trials that are evaluating new therapies.

11 September 2022 in EJNMMI Research
Verified
Journal Article
Open access
PDF file
JEJakoba J. Eertink
Jakoba J. Eertink
MHMartijn W. Heymans
Martijn W. Heymans
GZGerben J. C. Zwezerijnen
Gerben J. C. Zwezerijnen
JZJosée M. Zijlstra
Josée M. Zijlstra
HVHenrica C. W. de Vet
Henrica C. W. de Vet
RBRonald Boellaard
Ronald Boellaard
Aim: Clinical prediction models need to be validated. In this study, we used simulation data to compare various internal and external validation approaches to validate models. Methods: Data of 500 patients were simulated using distributions of metabolic tumor volume, standardized uptake value, the maximal distance between the largest lesion and another lesion, WHO performance status and age of 296 diffuse large B cell lymphoma patients. These data were used to predict progression after 2 years based on an existing logistic regression model. Using the simulated data, we applied cross-validation, bootstrapping and holdout (n = 100). We simulated new external datasets (n = 100, n = 200, n = 500) and simulated stage-specific external datasets (1), varied the cut-off for high-risk patients (2) and the false positive and false negative rates (3) and simulated a dataset with EARL2 characteristics (4). All internal and external simulations were repeated 100 times. Model performance was expressed as the cross-validated area under the curve (CV-AUC ± SD) and calibration slope. Results: The cross-validation (0.71 ± 0.06) and holdout (0.70 ± 0.07) resulted in comparable model performances, but the model had a higher uncertainty using a holdout set. Bootstrapping resulted in a CV-AUC of 0.67 ± 0.02. The calibration slope was comparable for these internal validation approaches. Increasing the size of the test set resulted in more precise CV-AUC estimates and smaller SD for the calibration slope. For test datasets with different stages, the CV-AUC increased as Ann Arbor stages increased. As expected, changing the cut-off for high risk and false positive- and negative rates influenced the model performance, which is clearly shown by the low calibration slope. The EARL2 dataset resulted in similar model performance and precision, but calibration slope indicated overfitting. Conclusion: In case of small datasets, it is not advisable to use a holdout or a very small external dataset with similar characteristics. A single small testing dataset suffers from a large uncertainty. Therefore, repeated CV using the full training dataset is preferred instead. Our simulations also demonstrated that it is important to consider the impact of differences in patient population between training and test data, which may ask for adjustment or stratification of relevant variables.

6 January 2022 in Journal of Nuclear Medicine
Verified
Journal Article
Closed access
PDF file
JDJulia Driessen
Julia Driessen
GZGerben JC Zwezerijnen
Gerben JC Zwezerijnen
HSHeiko Schöder
Heiko Schöder
EDEsther E.E. Drees
Esther E.E. Drees
MKMarie José Kersten
Marie José Kersten
RBRonald Boellaard
Ronald Boellaard
Introduction: Consensus about a standard segmentation method to derive metabolic tumor volume (MTV) in classical Hodgkin lymphoma (cHL) is lacking, and it is unknown how different segmentation methods influence quantitative PET features. Therefore, we aimed to evaluate the delineation and completeness of lesion selection and the need for manual adaptation with different segmentation methods, and to assess the influence of segmentation methods on the prognostic value of MTV, intensity and dissemination radiomics features in cHL patients. Methods: We analyzed a total of 105 18F-FDG PET-CT scans from patients with newly diagnosed (n = 35) and relapsed/refractory (n = 70) cHL with six segmentation methods: two fixed thresholds on SUV4.0 and SUV2.5, two relative methods of 41% of SUVmax (41max), and a contrast-corrected 50% of SUVpeak (A50P) and two combination ‘majority vote’ methods (MV2, MV3). Segmentation quality was assessed by two reviewers based on pre-defined quality criteria: completeness of selection, the need for manual adaptation and delineation of lesion borders. Correlations and prognostic performance of resulting radiomics features were compared among the methods. Results: SUV4.0 required the least manual adaptation but tended to underestimate MTV and often missed small lesions with low FDG uptake. SUV2.5 most frequently included all lesions but required minor manual adaptations and generally overestimated MTV. In contrast, few lesions were missed when using 41max, A50P, MV2 and MV3, but these segmentation methods required extensive manual adaptation and overestimated MTV in most cases. MTV and dissemination features significantly differed among the methods. However, correlations among methods were high for MTV and most intensity and dissemination features. There were no significant differences in prognostic performance for all features among the methods. Conclusion: There is a high correlation between MTV, intensity and most dissemination features derived with the different segmentation methods and the prognostic performance is similar. Despite frequently missing small lesions with low FDG avidity, segmentation with a fixed threshold of SUV4.0 required the least manual adaptation, which is critical for future research and implementation in clinical practice. However, the importance of small, low-avid lesions should be addressed in a larger cohort of cHL patients.

31 March 2023 in Blood
Verified
Journal Article
Open access
PDF file
JEJakoba Johanna Eertink
Jakoba Johanna Eertink
GZGerben JC Zwezerijnen
Gerben JC Zwezerijnen
MHMartijn Heymans
Martijn Heymans
SPSimone Pieplenbosch
Simone Pieplenbosch
SWSanne Elisabeth Wiegers
Sanne Elisabeth Wiegers
JZJosée M. Zijlstra
Josée M. Zijlstra
The objective of this study was to externally validate the clinicalPET model developed in the HOVON-84 trial and to compare the model performance of our clinicalPET model to the international prognostic index (IPI). In total, 1195 Diffuse large B-cell lymphoma patients were included. 887 patients from 6 studies were used as external validation datasets. Primary outcomes were 2-year progression free survival (PFS) and 2-year time to progression (TTP). Metabolic tumor volume (MTV), the maximum distance between the largest lesion and another lesion (Dmaxbulk) and the peak standardized uptake value (SUVpeak) were extracted. The predictive value of the IPI and the HOVON-84 clinicalPET model (MTV, Dmaxbulk, SUVpeak, performance status and age) were tested. Model performance was assessed using the area under the curve (AUC), and diagnostic performance with the positive predictive value (PPV). Using 2-year PFS as outcome, the IPI yielded an AUC of 0.62 (range:0.51-0.65). The clinicalPET model yielded a significantly higher AUC of 0.71 (range:0.59-0.75, p<0.001). Comparable results were found using 2-year TTP. High-risk IPI patients had a 2-year PFS of 61.4%, versus 51.9% for the high-risk clinicalPET patients, with an increase in PPV from 35.5% to 49.1%, respectively. 66.4% of high-risk IPI patients were free from progression or relapse versus 55.5% for high-risk clinicalPET patients, with an increased PPV from 33.7% to 44.6%, respectively. The clinicalPET model that was developed in the HOVON-84 dataset remained predictive of outcome in 6 independent first-line DLBCL studies, and had higher model performance than the currently used IPI in all studies.